AbbVie Inc. (ABBV) has been a topic of interest in the
stock market with individuals and investment firms increasing and decreasing their holdings. The company valuation was assessed post recent gains and holding after a pause, revealing a steady position. Moreover, ABBV's
dividend track record is appealing for indicating consistency, which attracted attention from investment houses such as Conning Inc., Eastern Bank, Forefront Analytics, among others. Despite some holdings being lowered by firms, others saw the potential to increase, contributing to the rising stock in September. However, it has experienced some dips which parallels market behavior broadly. AbbVie's expansion in manufacturing along with a stronger bet in US Biologics is touted to bolster its competitive edge in Oncology. Expected R&D hit has led to a trim in the annual profit forecast. Yet, ABBV continues to attract investors and hold stable ratings from several financial services. While there were some raises to the price target, the majority reiterated a 'Hold' position. ABBV has achieved
positive results in phase 2 trials and extended Rinvoq patent to 2037, delaying current generics.
Abbvie ABBV News Analytics from Tue, 17 Jun 2025 07:00:00 GMT to Sat, 11 Oct 2025 11:33:20 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 2
